Analysts Set Schrodinger, Inc. (NASDAQ:SDGR) PT at $20.25

Shares of Schrodinger, Inc. (NASDAQ:SDGR) have earned an average recommendation of “Hold” from the nine brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $20.25.

Several brokerages have weighed in on SDGR. Wall Street Zen downgraded Schrodinger from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Weiss Ratings upgraded shares of Schrodinger from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Finally, Morgan Stanley lowered their price target on shares of Schrodinger from $19.00 to $17.00 and set an “equal weight” rating for the company in a report on Thursday, May 14th.

Schrodinger Trading Up 8.6%

SDGR opened at $17.81 on Friday. Schrodinger has a 12 month low of $10.94 and a 12 month high of $23.02. The business’s 50-day moving average price is $15.63 and its 200-day moving average price is $13.70. The company has a market cap of $1.31 billion, a P/E ratio of -24.07 and a beta of 1.63.

Schrodinger (NASDAQ:SDGR) last issued its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.49. Schrodinger had a negative return on equity of 16.32% and a negative net margin of 20.98%.The company had revenue of $58.89 million during the quarter, compared to analysts’ expectations of $47.19 million. During the same period in the prior year, the business posted ($0.65) EPS. Schrodinger’s quarterly revenue was up 7.5% compared to the same quarter last year. Equities research analysts forecast that Schrodinger will post -1.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Schrodinger

A number of hedge funds have recently modified their holdings of SDGR. EverSource Wealth Advisors LLC boosted its holdings in shares of Schrodinger by 722.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,374 shares of the company’s stock worth $25,000 after purchasing an additional 1,207 shares during the period. Los Angeles Capital Management LLC purchased a new position in Schrodinger during the 4th quarter valued at about $26,000. Hantz Financial Services Inc. increased its holdings in Schrodinger by 5,025.8% during the 4th quarter. Hantz Financial Services Inc. now owns 1,589 shares of the company’s stock valued at $28,000 after purchasing an additional 1,558 shares during the period. State of Wyoming bought a new position in Schrodinger during the 2nd quarter valued at approximately $39,000. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in Schrodinger during the 4th quarter valued at approximately $36,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Key Stories Impacting Schrodinger

Here are the key news stories impacting Schrodinger this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Schrödinger reported adjusted earnings of $0.08 per share, compared with analysts’ expectation of a loss, while revenue reached $58.9 million versus the $47.2 million consensus estimate. Revenue increased 7.5% year over year, and the company moved from a $0.65-per-share loss in the prior-year quarter to a profit. Schrödinger Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Bristol Myers Squibb collaboration strengthens the AI drug-discovery story. Schrödinger announced a strategic collaboration and software agreement with BMS to deploy its Bunsen AI co-scientist for agentic drug discovery. The agreement provides commercial validation for Schrödinger’s software platform and could support future revenue growth and broader adoption of its AI capabilities. Schrödinger Announces Strategic Collaboration with Bristol Myers Squibb
• Positive Sentiment: Management’s earnings discussion reinforced the improved quarter. The earnings presentation and call highlighted the results, profitability shift and strategic AI developments, giving investors additional detail following the release. Schrödinger Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Despite the quarterly profit, Schrödinger remains unprofitable on broader trailing measures, with negative net margin and return on equity. Investors will likely focus on whether the BMS agreement and improving software performance can produce durable profitability.

About Schrodinger

Schrödinger, Inc is a life sciences and materials discovery company that specializes in the application of physics-based computational platforms to accelerate drug discovery and advanced materials design. Founded in 1990 by Professor Richard A. Friesner, Schrödinger has developed a suite of proprietary software tools—such as Maestro for molecular modeling, Glide for molecular docking and Jaguar for quantum chemistry calculations—that enable scientists to predict molecular behavior with high accuracy.